16 results match your criteria centrally hypoactive

  • Page 1 of 1

Intranasal Niosomal Gel as a Promising Approach for Enhancing Flibanserin Bioavailability and Brain Delivery: In Vitro Optimization and / Evaluation.

Pharmaceutics 2020 May 27;12(6). Epub 2020 May 27.

Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.

Flibanserin (FLB) is a multifunctional serotonergic agent that was recently approved by the FDA for the oral treatment of premenopausal women with hypoactive sexual desire disorder. FLB is a centrally acting drug that has a low oral bioavailability of 33% owing to its exposure to the hepatic first-pass effect, as well as its pH-dependent solubility, which could be an obstacle hindering the drug dissolution and absorption via mucosal barriers. Thus, this work aimed at overcoming the aforementioned drawbacks and promoting the nose-to-brain delivery of FLB via the formulation of an intra-nasal in situ niosomal gel. Read More

View Article and Full-Text PDF

Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.

Harry A Croft

J Sex Med 2017 12;14(12):1575-1584

CNS Studies, Clinical Trials of Texas Research Center, San Antonio, TX, USA. Electronic address:

Background: The neurobiology of sexual response is driven in part by dopamine and serotonin-the former modulating excitatory pathways and the latter regulating inhibitory pathways. Neurobiological underpinnings of hypoactive sexual desire disorder (HSDD) are seemingly related to overactive serotonin activity that results in underactive dopamine activity. As such, pharmacologic agents that decrease serotonin, increase dopamine, or some combination thereof, have therapeutic potential for HSDD. Read More

View Article and Full-Text PDF
December 2017

New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin.

Int J Womens Health 2017 10;9:171-178. Epub 2017 Apr 10.

Reproductive Solutions Inc., Midland, TX, USA.

The objective of the authors is to highlight the historical complexities for the diagnosis and treatment of hypoactive sexual desire disorder (HSDD) with a focus on Flibanserin. A systematic review of the medical literature published in PubMed using the search terms HSDD and Flibanserin was conducted. Each author reviewed the results of the systematic review for articles to include in this study. Read More

View Article and Full-Text PDF

Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment.

Sex Med Rev 2016 04 6;4(2):103-120. Epub 2016 Feb 6.

Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, USA.

Introduction: Hypoactive Sexual Desire Disorder (HSDD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) as persistent deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), HSDD has been subsumed by Female Sexual Interest/Arousal Disorder. However, decades of research based on DSM-IV-TR HSDD criteria form the foundation of our understanding of the essential symptom of distressing low sexual desire, its epidemiology, clinical management, and treatment. Read More

View Article and Full-Text PDF

The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

CNS Drugs 2015 Nov;29(11):915-33

Department of Psychology, Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC, Canada.

How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological factors; misregulation of any of these components could result in sexual dysfunction. Read More

View Article and Full-Text PDF
November 2015

Marine-Lenhart syndrome with papillary thyroid carcinoma.

J Res Med Sci 2015 Apr;20(4):412-5

Department of Nuclear Medicine, Ondokuz Mayis University Medical School, Samsun, Turkey.

Graves' disease with accompanying functioning nodules is known as Marine-Lenhart syndrome. Autonomously functioning thyroid nodules (AFTNs) also within Graves' thyroid tissue are almost always bening in nature. A 45-year-old man developed hyperthyroidism due to the coexistence of Graves' disease and AFTN. Read More

View Article and Full-Text PDF

Flibanserin for female sexual dysfunction.

C Reviriego

Drugs Today (Barc) 2014 Aug;50(8):549-56

Freelance Writer, Guilford, UK.

Hypoactive sexual desire disorder (HSDD) is the most commonly described form of female sexual dysfunction. There is currently no pharmacological therapy approved to treat HSDD, and therefore, there is an unmet medical need for the development of efficacious treatment alternatives. Flibanserin is a novel, non-hormonal drug for the treatment of HSDD in pre- and postmenopausal women, although the application submitted to the U. Read More

View Article and Full-Text PDF

Individual and dyadic barriers to a pharmacotherapeutic treatment of hypoactive sexual desire disorders: results and implications from a small-scale study with bupropion.

J Sex Marital Ther 2012 ;38(4):325-48

Department of Clinical Psychology, Hannover Medical School, Hannover, Germany.

This article describes the results of an independent small-scale trial with the centrally acting agent bupropion for female hypoactive sexual desire disorder. The main goals were to gain insight into the intrapsychic and interpersonal barriers to improvement associated with the pharmacological treatment of this common disorder. Eligible subjects entered a 2-week run-in period and a 4-week placebo phase, followed by a 20-week treatment phase. Read More

View Article and Full-Text PDF
October 2012

Low sexual desire--is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder.

James A Simon

Postgrad Med 2010 Nov;122(6):128-36

Department of Obstetrics and Gynecology, George Washington University, Washington, DC 20036, USA.

Hypoactive sexual desire disorder (HSDD) is thought to be the most prevalent form of female sexual dysfunction (FSD), affecting up to 1 in 10 US women. Hypoactive sexual desire disorder is defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) as persistent or recurrent deficiency or absence of sexual fantasies and thoughts, and/or desire for, or receptivity to, sexual activity, which causes personal distress or interpersonal difficulties and is not caused by a medical condition or drug. This definition has recently received criticism and recommendations for changes encompass the inclusion of duration, intensity, and frequency, and the elimination of distress as a diagnostic criterion. Read More

View Article and Full-Text PDF
November 2010

RAG2 gene knockout in mice causes fatigue.

Muscle Nerve 2007 Oct;36(4):471-6

Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA.

The effect of a disrupted immune system on the neuromuscular system is poorly characterized. We compared the strength and fatigue of RAG2(-/-) mice, which lack T-cells and B-cells, with immune intact controls. RAG2(-/-) mice demonstrated fatigue with shorter inverted hang-times (HT) and voluntary wheel-running (VWR) distance and total run times; they increased body weight more slowly but had proportionally normal forelimb grip strength (FGS) and VWR speed. Read More

View Article and Full-Text PDF
October 2007

The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys.

J Pharmacol Exp Ther 2007 Jun 20;321(3):1179-82. Epub 2007 Mar 20.

Research Institute of Biological Psychiatry, Sct. Hans Hospital, Roskilde, Denmark.

Cholinergic receptors (AChR) are reported altered in brains from schizophrenic patients, and a growing body of evidence suggests that muscarinic receptor agonists exhibit antipsychotic potential. Centrally acting selective muscarinic receptor agonists are currently not available for clinical use, but acetylcholinesterase (AChE) inhibitors, which indirectly stimulate AChR by blocking the breakdown of acetylcholine by AChE, are widely used in the clinic against Alzheimer's disease. AChE inhibitors have been reported to exhibit antipsychotic efficacy in Alzheimer's disease patients, and these compounds have also been investigated as adjunctive treatment to antipsychotic medication in schizophrenic patients with varying results. Read More

View Article and Full-Text PDF

Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment.

Pharmacol Biochem Behav 2005 Aug;81(4):917-22

Department of Psychiatry, CB# 7175, Medical Research Building A, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7175, USA.

Animal studies exploring the antagonism of irreversible cholinesterase inhibitors (i.e. nerve agents) such as soman and sarin have shown that pretreatment with the reversible centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic drug, scopolamine, antagonizes the lethality and toxicity of these agents. Read More

View Article and Full-Text PDF

Sexual dysfunction in the older woman: an overview of the current understanding and management.

Drugs Aging 2004 ;21(10):655-75

University of Wisconsin School of Medicine, Madison, Wisconsin, USA.

Sexuality is one of the most important quality of life issues for both men and women. Sexual dysfunction is a highly prevalent, age-related and progressive problem. The various physiological and psychological changes that occur with aging can have a significant impact on sexual function. Read More

View Article and Full-Text PDF

Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.

J Neurosci 2002 Jan;22(2):592-9

Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

Ablative and chronic stimulation procedures targeting the internal pallidum (GPi) and the subthalamic nucleus (STN) have led to major advancements in the treatment of Parkinson's disease and other movement disorders. Although these procedures have evolved to primarily target the posterior ventrolateral sensorimotor portion of GPi and to less selectively target STN, centrally, the ideal targets within these structures remain to be fully established. In this study, we sought to identify the optimal targeting sites in GPi and STN for reversal of parkinsonian signs through a series of reversible injections of the GABA(A) agonist muscimol in these nuclei in parkinsonian primates. Read More

View Article and Full-Text PDF
January 2002

Sexual pharmacology in the 21st century.

R C Rosen

J Gend Specif Med 2000 Jul-Aug;3(5):45-52

Department of Psychiatry, Center for Sexual and Marital Health, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Sexual dysfunction is highly prevalent in both sexes. Considerable progress has been made in the development of new pharmacologic treatments since the approval of sildenafil in 1998. A variety of oral erectogenic agents are available or are in late-phase development, including centrally active dopamine agonists (e. Read More

View Article and Full-Text PDF

The effects of centrally acting drugs on tremor in monkeys with mesencephalic lesions.

Proc Natl Acad Sci U S A 1969 Aug;63(4):1113-6

The effects of centrally acting drugs on tremor were investigated in monkeys with ventromedial tegmental lesions exhibiting hypokinesia or hypokinesia and tremor. In monkeys with resting tremor, the administration of DL-5-HTP (5-hydroxytryptophan) or of DL-DOPA (3,4-dihydroxyphenylalanine) relieves the tremor, but the simultaneous administration of DL-5-HTP or DL-DOPA and atropine results in a much more pronounced relief. These results point to an imbalance between the cholinergic and adrenergic-serotonergic systems in parkinsonism. Read More

View Article and Full-Text PDF
  • Page 1 of 1